Long-term treatment with olsalazine for ulcerative colitis: safety and relapse prevention: a follow-up study.

In a published placebo-controlled study comprising 101 patients, olsalazine was shown to possess relapse-preventing properties superior to placebo and similar to those of sulphasalazine. This is a retrospective follow-up of the 76 patients who continued olsalazine treatment on an open basis. The relapse pattern is similar to that of patients on sulphasalazine treatment, and the long-term tolerance and safety are encouraging.

RCT Entities:   Population Interventions Outcomes